Next Article in Journal
CXCR3 Provides a Competitive Advantage for Retention of Mycobacterium tuberculosis-Specific Tissue-Resident Memory T Cells Following a Mucosal Tuberculosis Vaccine
Next Article in Special Issue
Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season
Previous Article in Journal
Acceptance of the COVID-19 Vaccine by Prisoners and Staff in Spanish Prisons
Previous Article in Special Issue
Human Respiratory Syncytial Virus Epidemiological Burden in Pediatric Outpatients in Italy: A Systematic Review
 
 
Article

Article Versions Notes

Vaccines 2023, 11(10), 1548; https://doi.org/10.3390/vaccines11101548
Action Date Notes Link
article xml file uploaded 29 September 2023 13:18 CEST Original file -
article xml uploaded. 29 September 2023 13:18 CEST Update https://www.mdpi.com/2076-393X/11/10/1548/xml
article pdf uploaded. 29 September 2023 13:18 CEST Version of Record https://www.mdpi.com/2076-393X/11/10/1548/pdf
article html file updated 29 September 2023 13:20 CEST Original file https://www.mdpi.com/2076-393X/11/10/1548/html
Back to TopTop